Contribution of rat pulmonary metabolism to the elimination of lidocaine, midazolam, and nifedipine

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1183-1188

  Aoki, Makoto ^a   Okudaira, Kazuho ^b   Haga, Makoto ^c   Nishigaki, Ryuichiro ^b   Hayashi, Masahiro ^d  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; MIDAZOLAM; NIFEDIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LUNG; MALE; MICROSOME; NONHUMAN; PORTAL VEIN; PREDICTION; PRIORITY JOURNAL; RAT; ANIMAL; DRUG ADMINISTRATION ROUTE; DRUG SCREENING; FORECASTING; LIVER MICROSOME; METABOLISM; PROCEDURES; WISTAR RAT;

RATTUS;

ANIMALS; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; FORECASTING; IN VITRO TECHNIQUES; LIDOCAINE; LUNG; MALE; MICROSOMES; MICROSOMES, LIVER; MIDAZOLAM; NIFEDIPINE; RATS; RATS, WISTAR;

EID: 77953761336     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.032227     Document Type: Article

References (40)

1. Aiba T, Takehara Y, Okuno M, and Hashimoto Y (2003) Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20:745-748.
2. Albores A, Sinal CJ, Cherian MG, and Bend JR (1995) Selective increase of rat lung cytochrome P450 1A1 dependent monooxygenase activity after acute sodium arsenite administration. Can J Physiol Pharmacol 73:153-158.
3. Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, and Raunio H (1997) Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 16:242-249.
4. Austin RP, Barton P, Cockroft SL, Wenlock MC, and Riley RJ (2002) The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos 30:1497-1503.
5. Cassidy MK and Houston JB (1980) In vivo assessment of extrahepatic conjugative metabolism in first pass effects using the model compound phenol. J Pharm Pharmacol 32:57-59.
6. Debri K, Boobis AR, Davies DS, and Edwards RJ (1995) Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem Pharmacol 50:2047-2056.
7. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, and Nijsen MJ (2007) The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35:649-659.
8. Dees JH, Masters BS, Muller-Eberhard U, and Johnson EF (1982) Effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin and phenobarbital on the occurrence and distribution of four cytochrome P-450 isozymes in rabbit kidney, lung, and liver. Cancer Res 42:1423-1432. (Pubitemid 12148786)
9. De Kanter R, Monshouwer M, Draaisma AL, De Jager MH, de Graaf IA, Proost JH, Meijer DK, and Groothuis GM (2004) Prediction of whole-body metabolic clearance of drugs through the combined use of slices from rat liver, lung, kidney, small intestine and colon. Xenobiotica 34:229-241.
10. de Leede LG, de Boer AG, Roozen CP, and Breimer DD (1983) Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats. J Pharmacol Exp Ther 225:181-185.
11. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, and Beaune PH (1990) Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 253:387-394.
12. Domin BA, Devereux TR, and Philpot RM (1986) The cytochrome P-450 monooxygenase system of rabbit lung enzyme components, activities, and induction in the nonciliated bronchiolar epithelial (Clara) cell, alveolar type II cell, and alveolar macrophage. Mol Pharmacol 30:296-303.
13. Funae Y, Seo R, and Imaoka S (1985) Multiple forms of cytochrome P-450 from microsomes of rat liver, kidney, and lung resolved by high-performance liquid chromatography. Biochem Int 11:523-531. (Pubitemid 16227189)
14. Geddes DM, Nesbitt K, Traill T, and Blackburn JP (1979) First pass uptake of 14C-propranolol by the lung. Thorax 34:810-813. (Pubitemid 10217438)
15. Gibaldi M and Perrier D (1982) Clearance concepts, in Pharmacokinetics (Swarbric J ed) pp 567-580, Marcel Dekker, New York.
16. Grundy JS, Eliot LA, and Foster RT (1997) Extrahepatic first-pass metabolism of nifedipine in the rat. Biopharm Drug Dispos 18:509-522.
17. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
18. Higashikawa F, Murakami T, Kaneda T, Kato A, and Takano M (1999) Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J Pharm Pharmacol 51:67-72. (Pubitemid 29097271)
19. Imaoka S, Terano Y, and Funae Y (1989) Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. J Biochem 105:939-945. (Pubitemid 19147424)
20. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
21. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Baner K, Benet LZ, Sewing KF, and Christians U (1999) Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 291:131-139.
22. Jorfeldt L, Lewis DH, Löfström JB, and Post C (1979) Lung uptake of lidocaine in healthy volunteers. Acta Anaesthesiol Scand 23:567-574. (Pubitemid 10132235)
23. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, and Greenblatt DJ (2002) In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237.
24. Krishna DR and Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144-160.
25. Lê KT, Maurice H, and du Souich P (1996) First-pass metabolism of lidocaine in the anesthetized rabbit. Contribution of the small intestine. Drug Metab Dispos 24:711-716.
26. Lin JH, Sugiyama Y, Hanano M, and Awazu S (1984) Effect of product inhibition on elimination kinetics of ethoxybenzamide in rabbits. Analysis by physiological pharmacokinetic model. Drug Metab Dispos 12:253-256. (Pubitemid 14136547)
27. Macé K, Bowman ED, Vautravers P, Shields PG, Harris CC, and Pfeifer AM (1998) Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 34:914-920.
28. Mahnke A, Strotkamp D, Roos PH, Hanstein WG, Chabot GG, and Nef P (1997) Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver. Arch Biochem Biophys 337:62-68.
29. Mistry M and Houston JB (1985) Quantitation of extrahepatic metabolism. Pulmonary and intestinal conjugation of naphthol. Drug Metab Dispos 13:740-745.
30. Murata M, Tamai I, Sai Y, Nagata O, Kato H, Sugiyama Y, and Tsuji A (1998) Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab Dispos 26:1113-1119.
31. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, and Sugiyama Y (2001) Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316-1324. (Pubitemid 32896581)
32. Nestorov I, Gueorguieva I, Jones HM, Houston B, and Rowland M (2002) Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data. Drug Metab Dispos 30:276-282.
33. Nhamburo PT, Kimura S, McBride OW, Kozak CA, Gelboin HV, and Gonzalez FJ (1990) The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29:5491-5499.
34. Perreault S, Dumont L, Villiere V, Ong H, Adam A, and du Souich P (1993) Hepatic and extrahepatic metabolism of salbutamol in anesthetized rabbits. Drug Metab Dispos 21:485-491.
35. Raoof AA, Augustijns PF, and Verbeeck RK (1996) In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Pharm Res 13:891-895.
36. Shand DG, Kornhauser DM, and Wilkinson GR (1975) Effects of route of administration and blood flow on hepatic drug elimination. J Pharmacol Exp Ther 195:424-432.
37. Tanaka K, Oda Y, Asada A, Fujimori M, and Funae Y (1994) Metabolism of lidocaine by rat pulmonary cytochrome P450. Biochem Pharmacol 47:1061-1066.
38. Ueno T and Gonzalez FJ (1990) Complete sequence of the rat CYP2A3 gene specifically transcribed in lung. Nucleic Acids Res 18:4623-4624. (Pubitemid 20306352)
39. Verschoyle RD, Dinsdale D, and Wolf CR (1993) Inhibition and induction of cytochrome P450 isoenzymes in rat lung. J Pharmacol Exp Ther 265:386-391. (Pubitemid 23320986)
40. Zeldin DC, Foley J, Ma J, Boyle JE, Pascual JM, Moomaw CR, Tomer KB, Steenbergen C, and Wu S (1996) CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 50:1111-1117.